<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570219</url>
  </required_header>
  <id_info>
    <org_study_id>PS05BENVAL</org_study_id>
    <secondary_id>KLnro47/2005</secondary_id>
    <nct_id>NCT00570219</nct_id>
  </id_info>
  <brief_title>The Effect of Valproate on Benzodiazepine Withdrawal Severity</brief_title>
  <official_title>The Effect of Valproate Treatment on Withdrawal Severity in Benzodiazepine Dependent Opioid Maintenance Treatment Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether valproate is effective in the treatment of&#xD;
      benzodiazepine withdrawal symptoms in subjects receiving maintenance treatment for opiate&#xD;
      dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Finland, 90% of subjects with opioid dependence are dependent on benzodiazepines too.&#xD;
      Concurrent use of opioids and benzodiazepines has increasingly caused deaths.&#xD;
&#xD;
      Benzodiazepine withdrawal treatment usually comprises gradual drug discontinuation. In one&#xD;
      study, valproate was shown to improve benzodiazepine discontinuation success in chronic&#xD;
      benzodiazepine users. In the present study, the effectiveness of gradual benzodiazepine&#xD;
      discontinuation combined with valproate treatment and carried out in an inpatient setting is&#xD;
      compared with gradual discontinuation without pharmacological augmentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>benzodiazepine withdrawal severity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>benzodiazepine use</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>attrition from treatment</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gradual benzodiazepine discontinuation and valproate treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Gradual benzodiazepine discontinuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproate</intervention_name>
    <description>Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Deprakine depot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of benzodiazepine dependence (DSM IV-R)&#xD;
&#xD;
          -  Induction of buprenorphine or methadon maintenance treatment, or need of&#xD;
             benzodiazepine withdrawal treatment during ongoing buprenorphine/methadon maintenance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of convulsions&#xD;
&#xD;
          -  Unstable somatic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Vorma, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deputy chief physician, Helsinki University Central Hospital, Department of Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katila Heikki, Md, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Chief medical officer, Helsinki University Central Hospital, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Department of Psychiatry, Psychiatric Unit for Drug Dependence</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>09</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Helena Vorma (principal investigator)</name_title>
    <organization>Helsinki University Central Hospital, Department of Psychiatry</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

